



## **Press release**

### **Number of shares and votes in Orexo**

**Uppsala, Sweden – October 31, 2013** - The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company's incentive programs.

Today, the last trading day of the month, there are in total 32,678,941 shares and votes in the company.

#### **For further information, please contact:**

Henrik Juuel, EVP and Chief Financial Officer

Tel: +46 (0)722-20 94 77, E-mail: [henrik.juuel@orexo.com](mailto:henrik.juuel@orexo.com)

#### **About Orexo**

Orexo is an emerging specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery technology and commercial operations in the United States. The company is commercializing its proprietary product, Zubsolv<sup>®</sup> (buprenorphine and naloxone), for maintenance treatment of opioid dependence, in the United States. Zubsolv is a novel formulation of buprenorphine and naloxone using Orexo's extensive knowledge in sublingual technologies. Orexo has a portfolio of two approved and revenue generating products currently marketed under license in the EU and US. Orexo AB, with its headquarters in Sweden, is listed on NASDAQ-OMX and OTC market in the US (ORXOY). The largest shareholders are Novo A/S and HealthCap.

For information about Orexo please visit [www.orexo.com](http://www.orexo.com)

*Orexo AB (publ) discloses the information provided herein pursuant to the Financial Instruments Trading Act and/or the Securities Markets Act. The information was submitted for publication at 4:30 pm CET on October 31, 2013.*